Globally, prematurity is the leading cause of death in children under the age of 5. Every year, an estimated 15 million babies are born preterm, and 1 million die due to complications resulting from their early birth. Despite its widespread use, the efficacy and safety of antenatal corticosteroids in low-resource settings is not widely known. This session focused on resolving the controversies about the efficacy and safety of antenatal corticosteroid (dexamethasone) when used in pregnant women at risk of preterm birth. Panelists shared their contextual experiences from the trial implementation and their implications for individual countries, and other low-resource settings.

Moderator: Dr. Femi Oladapo, Head of the Maternal and Perinatal Unit, World Health Organization





Panelists include:
Dr. Shabina Ariff
Associate Professor, Department of Pediatrics & Child Health
The Aga Khan University

Dr. Zahida Qureshi
Associate Professor, University of Nairobi

Dr. Adejumoke Idowu Ayede
Paediatrician/Neonatologist,
College of Medicine, University of Ibadan and University College Hospital Ibadan

Dr. Shivaprasad Goudar
Professor of Physiology & Director of Research,
J N Medical College, KLE Academy of Higher Education and Research


Presentation

ACS Action 1 Trial


Featured Resources

ACTION-1 trial
Cochrane review update 2020
WHO 2015 Recommendation on Interventions to Improve Preterm Birth Outcomes
Antenatal Corticosteroids Trial (ACT)